Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-03-13
2007-03-13
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S304000, C549S060000, C544S333000, C544S405000, C546S148000, C546S164000, C546S176000, C546S284100, C548S454000, C548S525000, C514S256000, C514S307000, C514S314000, C514S337000, C514S415000, C514S428000, C514S444000, C514S255050
Reexamination Certificate
active
11243746
ABSTRACT:
A compound of Formula (I)wherein R1, R2, R3, R4, R5, and R6are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
REFERENCES:
patent: 4880839 (1989-11-01), Tucker
patent: 5039691 (1991-08-01), Spagnuolo et al.
patent: 6323199 (2001-11-01), Lehmann et al.
patent: 6329534 (2001-12-01), Kym et al.
patent: 6380223 (2002-04-01), Dow et al.
patent: 6436986 (2002-08-01), Kym et al.
patent: 6506766 (2003-01-01), Coghlan et al.
patent: 6583180 (2003-06-01), Link et al.
patent: 2002/0156311 (2002-10-01), Link et al.
patent: 900594 (1984-09-01), None
patent: 0 154 528 (1985-03-01), None
patent: 0 154 528 (1985-03-01), None
patent: 0 253 500 (1991-02-01), None
patent: 0 253 503 (1991-12-01), None
patent: 2 146 987 (1984-09-01), None
patent: WO 96/19458 (1996-06-01), None
patent: WO 97/27852 (1997-08-01), None
patent: WO 98/54159 (1998-12-01), None
patent: WO 99/41256 (1999-02-01), None
patent: WO 00/32584 (2000-06-01), None
patent: WO 00/66522 (2000-11-01), None
patent: WO 02/02565 (2002-01-01), None
patent: WO 02/10143 (2002-02-01), None
patent: WO 02064550 (2002-08-01), None
Hamann, Lawrence, et al ; Discovery of a potent, Orally active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline(LG12107), J. Med Chem, 1999, 42, 210-212.
Pooley, Charlotte, et al; Discovery and Preliminary SAR Studies of a Novel Nonsteroidal Progesterone Receptor Antagonist Pharmacophore, J. Med. Chem 1998, 41, 3461-3466.
Edwards, James, P. et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists; The Effect of D-Ring Substituents, J. Med. Chem 1998, 41, 303-310.
Zhi, Lin, et al; 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists, J. Med. Chem 1998, 41, 291-302.
Zhi, Lin; et al 5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a Novel Class Of Nonsteroidal Progesterone Receptor Agonists: Effect of A-Ring Modification, J. Med. Chem 1999, 42, 1466-1472.
Tegley, Christopher, et al; 5-Benzylidene 1,2-Dihydrochromeno[3,4-f]quinolines, A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists; J. Med. Chem 1998, 41, 4354-4359.
Edwards, James, P. et al; Preparation, Resolution and Biological Evaluation of 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progestgerone Receptor Agonists: J. Med. Chem. 1998,41, 2779-2785.
Hamann, Lawrence, et al; Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines J. Med. Chem 1998, 41, 623-639.
English Translation of WO/02/10143.
Betageri Rajashekhar
Thomson David
Zhang Yan
Zindell Renee Michele
Boehringer Ingelheim Pharmaceuticals Inc.
Devlin Mary-Ellen
Habte Kahsay
Morris Michael P.
Witkowski Timothy X.
LandOfFree
Glucocorticoid mimetics, methods of making them,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucocorticoid mimetics, methods of making them,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucocorticoid mimetics, methods of making them,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802241